Johnny Christian, MD
Family Medicine · Waynesboro, GANPI 1962445841
Payments from drug & device makers
Across 236 payments — averaging $15.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$536
- Pfizer$392
- Novo Nordisk$348
- Boston Scientific$266
- Amgen$186
- AstraZeneca$165
- plus $2K from 31 others
What the payments were for
- Food & beverage$3,727100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 39 | $536 |
| Pfizer | 34 | $392 |
| Novo Nordisk | 22 | $348 |
| Boston Scientific | 5 | $266 |
| Amgen | 12 | $186 |
| AstraZeneca | 11 | $165 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $162 |
| Lilly USA, LLC | 11 | $160 |
| Otsuka America Pharmaceutical, Inc. | 7 | $146 |
| Sunovion Pharmaceuticals Inc. | 7 | $133 |
| Novartis | 9 | $123 |
| Dexcom, Inc. | 7 | $112 |
| Amarin Pharma, Inc. | 6 | $108 |
| Bayer | 5 | $101 |
| Abbott | 6 | $94 |
| Boehringer Ingelheim | 6 | $91 |
| GSK | 5 | $88 |
| Esperion Therapeutics, Inc. | 4 | $79 |
| E.r. Squibb & Sons, L.L.C. | 6 | $76 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Sanofi Pasteur Inc. | 2 | $30 |
| Antares Pharma, Inc. | 2 | $30 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $30 |
| Merck | 2 | $29 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Lundbeck LLC | 1 | $28 |
| Nestle Healthcare Nutrition Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $17 |
| Corium, LLC | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
| Johnson & Johnson | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,741 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,540 | $324,028 |
| OzempicSemaglutide | 120 | $130,555 |
| JardianceEmpagliflozin | 169 | $125,258 |
| FarxigaDapagliflozin Propanediol | 145 | $88,914 |
| MounjaroTirzepatide | 61 | $87,623 |
| JanuviaSitagliptin Phosphate | 205 | $74,185 |
| RexultiBrexpiprazole | 68 | $55,057 |
| MyrbetriqMirabegron | 178 | $50,840 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $32,263 |
| XareltoRivaroxaban | 73 | $22,437 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $19,121 |
| VraylarCariprazine Hcl | 13 | $18,350 |
| LinzessLinaclotide | 15 | $16,227 |
| Potassium Chloride | 1,334 | $16,106 |
| TrulicityDulaglutide | 11 | $14,745 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo, Premarin | $392 | $339,0481,577 claims |
| Novo NordiskOzempic, Rybelsus | $348 | $143,027132 claims |
| Boehringer IngelheimJardiance | $91 | $125,258169 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $165 | $106,696184 claims |
| Lilly USA, LLCMounjaro, Trulicity | $160 | $102,36972 claims |
| MerckJanuvia | $29 | $74,185205 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $146 | $55,05768 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $88 | $42,10542 claims |
| AbbVieVraylar, Linzess, Namzaric | $536 | $40,68639 claims |
| Johnson & JohnsonXarelto | $11 | $22,43773 claims |
| NovartisEntresto | $123 | $10,45244 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $11 | $5,82281 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Waynesboro
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.